HIV and AIDS Research News & Events
Learn about upcoming meetings relevant to HIV malignancies and recent news about NCI HIV/AIDS and HIV malignancy research.
18th International Conference on Malignancies in HIV/AIDS (ICMH)
October 24-26, 2022
Online Registration is required
Abstracts are due by August 26, 2022. Late abstracts will not be accepted.
Latest on the Anal Cancer/HSIL Outcomes Research (ANCHOR) Study:
NCI congratulates Dr. Enrique Mesri, Director of the University of Miami/Argentina AIDS Malignancies Consortium, for his lifetime achievement award (RAICES) from the Government of Argentina for his contributions to the country’s science in HIV/AIDS malignancies.
This year marks the 50th Anniversary of the United States National Cancer Act and NCI is commemorating this landmark legislation. As a result of this investment in cancer research, by the 1980s NCI was in a strong position to make advances in the fight against HIV/AIDS.
How Cancer Research Led to AIDS Breakthroughs
Although many doubted whether any drug could be developed to fight AIDS, Dr. Robert Yarchoan worked with Drs. Samuel Broder and Hiroaki Mitsuya on the first AIDS drugs, including azidothymidine (AZT), transforming a fatal disease into a chronic one.
A Diverse Workforce with a Shared Mission
The National Institutes of Health Office of AIDS Research (OAR) joins colleagues worldwide to commemorate to 40th anniversary of the landmark 1981 Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) that first recognized the syndrome of diseases as later named AIDS. Below are two MMWR relevant articles.
Pneumocystis Pneumonia-Los Angeles
Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men-New City and California
Learn how the AIDS and Cancer Specimen Resource (ACSR) developed new strategies to improve visibility by using a cross disciplinary approach.
Collaborating with a Graduate Marketing Class to Boost Awareness of the AIDS and Cancer Specimen Resource
Biopreservation and Biobanking
In celebration of World AIDS Day 2020, Dr. Robert Yarchoan provided a reflection on the history of HIV drugs developed at NCI, on HIV malignancies, and how HIV research is informing research on drugs against COVID.
Scientific Advances in HIV Detection and Treatment
Researchers in the HIV and AIDS Malignancy Branch, CCR reported trial results showing that treatment of aggressive HIV-associated primary central nervous lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate is associated with high response rate, CD4+ lymphocyte reconstitution, and long-term survival with preservation or improvement of neurocognitive function.
Treatment of HIV-associate Primary CNS Lymphoma with Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate
On May 14, 2020 FDA approves pomalidomide for AIDSrelated Kaposi sarcoma. The approval of Pomalyst was as a result of a Phase 1/2 clinical trial in patients with HIV-positive and HIV-negative symptomatic Kaposi sarcoma conducted by a team led by Dr. Robert Yarchoan of the HIV and AIDS Malignancy Branch.
Results from a large clinical trial supported by NCI and NIAID demonstrated that patients with advanced AIDS-associated Kaposi sarcoma have improved outcomes when treated with antiretroviral therapy and the chemotherapy drug paclitaxel.
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial
Commentary: Time to address disparities in the standard of care for Kaposi sarcoma